Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas

British Journal of Cancer

Volumn 109, Issue 2, 2013, Pages 472-481

  Kitada, S ^a   Yamada, S ^a   Kuma, A ^a   Ouchi, S ^b   Tasaki, T ^a   Nabeshima, A ^a   Noguchi, H ^a   Wang, K Y ^a   Shimajiri, S ^a,b   Nakano, R ^b   Izumi, H ^a   Kohno, K ^a   Matsumoto, T ^a   Sasaguri, Y ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

GalNAc T3; GalNAc T6; prognosis; renal cell carcinoma; vascular invasion

Indexed keywords

BETA CATENIN; CELL ADHESION MOLECULE; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE N ACETYLGALACTOSAMINYLTRANSFERASE 3; POLYPEPTIDE N ACETYLGALACTOSAMINYLTRANSFERASE 6; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84881084696     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.331     Document Type: Article

References (44)

1. Aubert S, Fauquette V, Hémon B, Lepoivre R, Briez N, Bernard D, Van Seuningen I, Leroy X, Perrais M (2009) MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 69(14): 5707-5715.
2. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP, van Engeland M (2008) Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 1785(2): 133-155.
3. Bennett EP, Hassan H, Clausen H (1996) cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N- acetylgalactosaminyltransferase GalNAc-t3. J Biol Chem 271(29): 17006-17012.
4. Bennett EP, Hassan H, Mandel U, Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG, Olofsson S, Clausen H (1999) Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha- Dgalactosamine: Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J Biol Chem 274(36): 25362-25370.
5. Bennett EP, Hassan H, Mandel U, Mirgorodskaya E, Roepstorff P, Burchell J, Taylor-Papadimitriou J, Hollingsworth MA, Merkx G, van Kessel AG, Eiberg H, Steffensen R, Clausen H (1998) Cloning of a human UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNActransferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem 273(46): 30472-30481.
6. Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H, Osinaga E (2006) UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem 54(3): 317-328.
7. Brockhausen I (1999) Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1473(1): 67-95.
8. Chow WH, Devesa SS, Warren JL, Fraumeni Jr. JF (1999) Rising incidence of renal cell cancer in the United States. Jama 281(17): 1628-1631.
9. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23): 2477-2490.
10. Dosaka-Akita H, Kinoshita I, Yamazaki K, Izumi H, Itoh T, Katoh H, Nishimura M, Matsuo K, Yamada Y, Kohno K (2002) N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer 87(7): 751-755.
11. Dwek RA (1996) Glycobiology: Toward understanding the function of sugars. Chem Rev 96(2): 683-720.
12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111.
13. Finley DS, Pantuck AJ, Belldegrun AS (2011) Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 16(Suppl 2): 4-13.
14. Freire T, Berois N, Sonora C, Varangot M, Barrios E, Osinaga E (2006) UDPN-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer 119(6): 1383-1388.
15. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7): 655-663.
16. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhaes A, Pinto-de-Sousa J, Almeida R, Gartner F, Reis CA (2009) Expression of UDP-N-acetyl-Dgalactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. J Histochem Cytochem 57(1): 79-86.
17. Grabenhorst E, Conradt HS (1999) The cytoplasmic, transmembrane, and stem regions of glycosyltransferases specify their in vivo functional sublocalization and stability in the Golgi. J Biol Chem 274(51): 36107-36116.
18. Gu C, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, Sugio K, Kohno K, Yasumoto K (2004) Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: Impact on poor prognosis and early recurrence. Br J Cancer 90(2): 436-442.
19. Hagen FK, Van Wuyckhuyse B, Tabak LA (1993) Purification, cloning, and expression of a bovine UDP-GalNAc: Polypeptide N- acetylgalactosaminyltransferase. J Biol Chem 268(25): 18960-18965.
20. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 4(1): 45-60.
21. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otsuji Y, Kohno K (2007) Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26(33): 4749-4760.
22. Inoue T, Eguchi T, Oda Y, Nishiyama K, Fujii K, Izumi H, Kohno K, Yamaguchi K, Tanaka M, Tsuneyoshi M (2007) Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections -special reference to its association with lymph node metastases. Mod Pathol 20(2): 267-276.
23. Ishikawa M, Kitayama J, Nariko H, Kohno K, Nagawa H (2004) The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: Polypeptide N- acetylgalactosaminyl transferase-3 in early gastric carcinoma. J Surg Oncol 86(1): 28-33.
24. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3): 452-458.
25. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA (2005) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114(6): 950-956.
26. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y (2011) Polypeptide N- acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer 104(12): 1882-1889.
27. Miyahara N, Shoda J, Kawamoto T, Furukawa M, Ueda T, Todoroki T, Tanaka N, Matsuo K, Yamada Y, Kohno K, Irimura T (2004) Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res 10(6): 2090-2099.
28. Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, Kidani A, Tawara A, Kohno K (2008) Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 283(26): 18218-18226.
29. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22): 3584-3590.
30. Naito S, Kanamori T, Hisano S, Tanaka K, Momose S, Kamata N (1982) Human renal cell carcinoma: Establishment and characterization of two new cell lines. J Urol 128(5): 117-1121.
31. Nomoto M, Izumi H, Ise T, Kato K, Takano H, Nagatani G, Shibao K, Ohta R, Imamura T, Kuwano M, Matsuo K, Yamada Y, Itoh H, Kohno K (1999) Structural basis for the regulation of UDP-N-acetyl-a-Dgalactosamine: Polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer Res 59(24): 6214-6222.
32. Park JH, Katagiri T, Chung S, Kijima K, Nakamura Y (2011) Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia 13(4): 320-326.
33. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T (2010) Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res 70(7): 2759-2769.
34. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA (2001) Glycosylation and the immune system. Science 291(5512): 2370-2376.
35. Schwientek T, Bennett EP, Flores C, Thacker J, Hollmann M, Reis CA, Behrens J, Mandel U, Keck B, Schäfer MA, Haselmann K, Zubarev R, Roepstorff P, Burchell JM, Taylor-Papadimitriou J, Hollingsworth MA, Clausen H (2002) Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans and mammals. J Biol Chem 277(25): 22623-22638.
36. Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, Matsuo K, Yamada Y, Kitazato K, Itoh H, Kohno K (2002) Expressions of UDP-NAcetyl-a-D- galactosaminepolypeptide GalNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer 94(7): 1939-1946.
37. Siegel R, Naishadham D, Jemal A (2012) Cancer Statistics 2012. CA Cancer J Clin 62(1): 10-29.
38. Sobin LH, Gospodarowicz MK, Wittekind Ch (2009) TNM Classification of Malignant Tumours. 7th edn (Wiley-Blackwell: Hoboken).
39. Ten Hagen KG, Fritz TA, Tabak LA (2003) All in the family: The UDPGalNAc: Polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13(1): 1R-16R.
40. Wandall HH, Dabelsteen S, Sorensen JA, Krogdahl A, Mandel U, Dadelsteen E (2007) Molecular basis for the presence of glycosylated onco-foetal fibronectin in oral carcinomas: The production of glycosylated onco-foetal fibronectin by carcinoma cells. Oral Oncol 43(3): 301-309.
41. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H (1997) Substrate specificities of three members of the human UDP-N-acetyl-a-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases family, GalNAc-T1, -T2, and -T3. J Biol Chem 272(38): 23503-23514.
42. Yamamoto S, Nakamori S, Tsujie M, Takahashi Y, Nagano H, Dono K, Umeshita K, Sakon M, Tomita Y, Hoshida Y, Aozasa K, Kohno K, Monden M (2004) Expression of uridine diphosphate N-acetyl-alpha-Dgalactosamine: Polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology 71(1): 12-18.
43. Yuan Z, Wong S, Borrelli A, Chung MA (2007) Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 362(3): 740-746.
44. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20(23): 4559-4566.